CA2361256A1 - Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 - Google Patents

Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 Download PDF

Info

Publication number
CA2361256A1
CA2361256A1 CA002361256A CA2361256A CA2361256A1 CA 2361256 A1 CA2361256 A1 CA 2361256A1 CA 002361256 A CA002361256 A CA 002361256A CA 2361256 A CA2361256 A CA 2361256A CA 2361256 A1 CA2361256 A1 CA 2361256A1
Authority
CA
Canada
Prior art keywords
ccr1
antagonist
disease
mice
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361256A
Other languages
English (en)
Inventor
James B. Rottman
Wayne W. Hancock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361256A1 publication Critical patent/CA2361256A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à une méthode de traitement des troubles inflammatoires démyélinisants. Cette méthode consiste à administrer à un sujet nécessitant un tel traitement une quantité efficace d'un antagoniste de la fonction CCR1. Dans une réalisation préférée, l'invention se rapporte à une méthode de traitement de la sclérose en plaques.
CA002361256A 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 Abandoned CA2361256A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24025399A 1999-01-29 1999-01-29
US09/240,253 1999-01-29
PCT/US2000/002124 WO2000044408A2 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Publications (1)

Publication Number Publication Date
CA2361256A1 true CA2361256A1 (fr) 2000-08-03

Family

ID=22905789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361256A Abandoned CA2361256A1 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Country Status (5)

Country Link
EP (1) EP1148889A2 (fr)
JP (1) JP2002535376A (fr)
AU (1) AU2740900A (fr)
CA (1) CA2361256A1 (fr)
WO (1) WO2000044408A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
AU2003240758B2 (en) 2002-04-04 2008-03-13 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
UY28170A1 (es) * 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
JPH09249570A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ベンゾジアゼピン化合物含有ケモカイン受容体拮抗剤
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2000044408A3 (fr) 2000-12-14
AU2740900A (en) 2000-08-18
EP1148889A2 (fr) 2001-10-31
WO2000044408A2 (fr) 2000-08-03
JP2002535376A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
CA2201781C (fr) Traitement de la polyarthrite rhumatoide contenant un antagoniste de l'il-6 comme agent actif
CA2211578C (fr) Agent inhibitant la proteolyse des proteines musculaires contenant un anticorps dirige contre le recepteur de l'il-6
US5888510A (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU773293B2 (en) Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) Modulation of systemic memory T cell trafficking
Okamoto et al. Molecular targets of rheumatoid arthritis
Grimaldi et al. Depletion of eosinophils in mice through the use of antibodies specific for C‐C chemokine receptor 3 (CCR3)
CA2577631A1 (fr) Procedes et compositions pour le traitement d'inflammation allergique
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
US20020055456A1 (en) Therapeutic methods that target fractalkine or CX3CR1
EP2367550B1 (fr) Inhibiteurs il-3 à utiliser pour le traitement de l'arthrite rhumatoïde à un stade précoce
US20020042370A1 (en) Method of treating graft rejection using inhibitors of CCR2 function
PL190617B1 (pl) Zastosowanie czynnika blokującego LT-beta-R, zastosowania kompozycji farmaceutycznej i kompozycja farmaceutyczna
CA2703705A1 (fr) Procedes de traitement de la sclerodermie
EP1030865A2 (fr) APPAUVRISSEMENT DE LA CELLULE Th2, COMPOSITIONS ET METHODES EN RAPPORT
AU2740900A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
MXPA01007565A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
Setoguchi et al. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component

Legal Events

Date Code Title Description
FZDE Dead